Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995-2001

Clinical Microbiology and Infection

Volumn 11, Issue 4, 2005, Pages 307-311

  Rimbara, E ^a   Noguchi, N ^a   Tanabe, M ^a   Kawai, T ^b   Matsumoto, Y ^c   Sasatsu, M ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c Hachioji Pharmaceut Ctr Pharmacy   (Japan)

Author keywords

Amoxycillin; Antimicrobial resistance; Clarithromycin; Helicobacter pylori; Metronidazole; Resistance

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SCHOOL CHILD; STOMACH ANTRUM; STOMACH BIOPSY;

HELICOBACTER PYLORI;

EID: 15944380807     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01099.x     Document Type: Article

References (27)

1. Graham DY, Lew GM, Klein PD et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992; 116: 705-708.
2. Kokkola A, Sipponen P, Rautelin H et al. The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment Pharmacol Ther 2002; 16: 515-520.
3. Bayerdorffer E, Neubauer A, Rudolph B et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995; 345: 1591-1594.
4. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789.
5. Asaka M, Satoh K, Sugano K et al. Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 2001; 6: 177-186.
6. Dore MP, Piana A, Carta M et al. Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 635-639.
7. Suzuki J, Mine T, Kobayasi I, Fujita T. Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H. pylori resistance to this therapy in Japan. Helicobacter 1998; 3: 59-63.
8. Poon SK, Chang CS, So J et al. Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. Aliment Pharmacol Ther 2002; 16: 291-296.
9. Queiroz DM, Dani R, Silva LD et al. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol 2002; 35: 315-320.
10. Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy - results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003; 17: 99-109.
11. Murakami K, Sato R, Okimoto T et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 2003; 17: 119-123.
12. Megraud F, Lehn N, Lind T et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43: 2747-2752.
13. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin - influence on treatment outcome. Am J Gastroenterol 1998; 93: 386-389.
14. Tankovic J, Lamarque D, Lascols C, Soussy CJ, Delchier JC. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Aliment Pharmacol Ther 2001; 15: 707-713.
15. Wong BC, Wang WH, Berg DE et al. High prevalence of mixed infections by Helicobacter pylori in Hong Kong: metronidazole sensitivity and overall genotype. Aliment Pharmacol Ther 2001; 15: 493-503.
16. Kim JJ, Kim JG, Kwon DH. Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing. Helicobacter 2003; 8: 202-206.
17. Ikezawa K, Kashimura H, Kojima M et al. Pretreatment antimicrobial susceptibilities of paired gastric Helicobacter pylori isolates: antrum versus corpus. Helicobacter 1999; 4: 218-221.
18. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; 12th informational supplement. M100-S12. Villanova, PA: NCCLS, 2002.
19. Kawai T, Kawakami K, Kudo T et al. Correlation between serum pepsinogen levels and gastric mucosal histological findings before and after Helicobacter pylori eradication therapy. Digest Endosc 2004; 16: 122-128.
20. Perez Aldana L, Kato M, Nakagawa S et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002; 7: 306-309.
21. Kato M, Yamaoka Y, Kim JJ et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000; 44: 2214-2216.
22. Stone GG, Shortridge D, Flamm RK et al. Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori. Helicobacter 1996; 1: 227-228.
23. Versalovic J, Shortridge D, Kibler K et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996; 40: 477-480.
24. Taylor DE, Ge Z, Purych D, Lo T, Hiratsuka K. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob Agents Chemother 1997; 41: 2621-2628.
25. Hardy RD, Rios AM, Chavez-Bueno S et al. Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia. Antimicrob Agents Chemother 2003; 47: 1614-1620.
26. Langtry HD, Brogden RN. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drugs 1997; 53: 973-1004.
27. Yanagihara K, Tomono K, Imamura Y et al. Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. J Antimicrob Chemother 2002; 49: 867-870.